The global blood stream infection testing market size was US$ 5 billion in 2021. The global blood stream infection testing market is expected to grow to US$ 9.1 billion by 2030, registering a compound annual growth rate (CAGR) of 9.3% during the study period, i.e., 2022-2030.
A blood stream infection is any bacterial, fungal, infection found in the blood. The sickness embodies as soon as the pathogen spreads the infection throughout the body. Testing for blood stream infections is done to find out which bacteria or other organisms are responsible for the blood infections. Blood stream infection can lead to chills, a cold, fever, diarrhea, vomiting, etc.

Factors Influencing the Market
The rising prevalence of bloodstream infections will primarily fuel the growth of the blood stream infection testing market during the study period. The U.S. National Library of Medicine estimates that bloodstream infections (BSIs) are among the leading causes of disease and mortality. Further, the growing geriatric population will open doors of opportunities for the blood stream infection testing market as the elderly population is more susceptible to infection.
Rising healthcare expenditure and increasing awareness about blood stream infection testing will contribute to the growth of the blood stream infection testing market during the analysis period.
The high cost of blood stream infection testing may restrict the market growth during the analysis period. On the contrary, growing technological advancements, combined with the growing investments, are expected to be opportunistic for the blood stream infection testing market.

Regional Analysis
North America is expected to hold the largest share in the blood stream infection testing market. The growth of the market is attributable to the rising geriatric population and the presence of advanced healthcare facilities in the region. Further, the growing geriatric population, combined with the increasing investments, is expected to unfold lucrative opportunities for the blood stream infection testing market during the study period.

COVID-19 Impact Analysis
The global blood stream infection testing market was positively affected by the blood stream infection testing market as blood culture test is claimed to be the significant standard for diagnosis. Additionally, it was discovered that COVID patients had a blood stream infection incidence rate of 0.863% as opposed to individuals without COVID who had a 0.437% incidence rate. Moreover, testing for blood stream infections is predicted to increase shortly due to the coronavirus's growing mutation.

Competitors in the Market
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
becton dickinson medical devices co. ltd., suzhou
bioMrieux SA
cepheid
Luminex Corporation
Accelerate Diagnostics Inc.
AdvanDx
Bruker Corporation
Other Prominent Players

Market Segmentation
The global blood stream infection testing market segmentation focuses on Technology, Product, Technique, Application, End-Users, and Region.
By Technology
Culture-based
Molecular
Proteomic
By Product
Instruments
Consumables
Software and Services
By Technique
Conventional
Automated
By Application
Bacterial
Fungal
Mycobacterial
By End-users
Hospitals
Independent Diagnostics Centers
Others
By Regional Outlook
? North America
o The U.S.
o Canada
o Mexico
? Europe
? Western Europe
o The UK
o Germany
o France
o Italy
o Spain
o Rest of Western Europe
? Eastern Europe
o Poland
o Russia
o Rest of Eastern Europe
? Asia Pacific
o China
o India
o Japan
o Australia & New Zealand
o ASEAN
o Rest of Asia Pacific
? Middle East & Africa (MEA)
o UAE
o Saudi Arabia
o South Africa
o Rest of MEA
? South America
o Brazil
o Argentina
o Rest of South America